Inhibitors of the coagulation factor XIIa (FXIIa) are attractive to detail the roles of this protease in hemostasis and thrombosis, to suppress artifact due to contact pathway activation in blood coagulation assays, and they are promising as antithrombotic therapy. The 3-carboxamide coumarins have been previously described as small-molecular-weight FXIIa inhibitors. In this study, we report a structure-activity relationship (SAR) study around this scaffold with the aim to discover new selective FXIIa inhibitors with an improved physico-chemical profile. To better understand these SAR, docking experiments were undertaken. For this purpose, we built an original hybrid model of FXIIa. This model has the advantage to gather the best features from the recently published crystal structure of FXIIa in its zymogen form and a more classical homology model. Results with the hybrid model are encouraging as they help understanding the activity and selectivity of our best compounds.
Original languageEnglish
Article number110
Pages (from-to)181-194
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - 3 Mar 2016


  • Coumarins; Factor XIIa; Factor XII; FXII; antithrombotic agents; benzopyrans


Dive into the research topics of 'Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors'. Together they form a unique fingerprint.

Cite this